Your browser doesn't support javascript.
loading
High expression of olfactomedin-4 is correlated with chemoresistance and poor prognosis in pancreatic cancer.
Ohkuma, Ryotaro; Yada, Erica; Ishikawa, Shumpei; Komura, Daisuke; Ishizaki, Hidenobu; Tamada, Koji; Kubota, Yutaro; Hamada, Kazuyuki; Ishida, Hiroo; Hirasawa, Yuya; Ariizumi, Hirotsugu; Satoh, Etsuko; Shida, Midori; Watanabe, Makoto; Onoue, Rie; Ando, Kiyohiro; Tsurutani, Junji; Yoshimura, Kiyoshi; Yokobori, Takehiko; Sasada, Tetsuro; Aoki, Takeshi; Murakami, Masahiko; Norose, Tomoko; Ohike, Nobuyuki; Takimoto, Masafumi; Izumizaki, Masahiko; Kobayashi, Shinichi; Tsunoda, Takuya; Wada, Satoshi.
Afiliação
  • Ohkuma R; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Yada E; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Ishikawa S; Department of Physiology, Graduate School of Medicine, Showa University, Tokyo, Japan.
  • Komura D; Kanagawa Cancer Center Research Institute, Kanagawa, Japan.
  • Ishizaki H; Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Tamada K; Department of Molecular Preventive Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
  • Kubota Y; Noile-Immune Biotech, Inc., Tokyo, Japan.
  • Hamada K; Department of Immunology, Graduate School of Medicine, Yamaguchi University, Yamaguchi, Japan.
  • Ishida H; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Hirasawa Y; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Ariizumi H; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Satoh E; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Shida M; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Watanabe M; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Onoue R; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Ando K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Tsurutani J; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Yoshimura K; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Yokobori T; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Sasada T; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Aoki T; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Murakami M; Department of Clinical Diagnostic Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Norose T; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Ohike N; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Takimoto M; Advanced Cancer Translational Research Institute, Showa University, Tokyo, Japan.
  • Izumizaki M; Department of Medicine, Division of Medical Oncology, School of Medicine, Showa University, Tokyo, Japan.
  • Kobayashi S; Department of Clinical Immuno Oncology, Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Tsunoda T; Clinical Research Institute for Clinical Pharmacology & Therapeutics, Showa University, Tokyo, Japan.
  • Wada S; Department of Innovative Immune-Oncology Therapeutics, Graduate School of Medicine, Gunma University, Gunma, Japan.
PLoS One ; 15(1): e0226707, 2020.
Article em En | MEDLINE | ID: mdl-31923206
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Regulação Neoplásica da Expressão Gênica / Fator Estimulador de Colônias de Granulócitos / Resistencia a Medicamentos Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pancreáticas / Regulação Neoplásica da Expressão Gênica / Fator Estimulador de Colônias de Granulócitos / Resistencia a Medicamentos Antineoplásicos Idioma: En Ano de publicação: 2020 Tipo de documento: Article